Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

Abstract Background Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA <100,000 copies/mL. In resource-limited settings, pre-treatment HIV RNA is not rout...

Full description

Bibliographic Details
Main Authors: Sasisopin Kiertiburanakul, David Boettiger, Oon Tek Ng, Nguyen Van Kinh, Tuti Parwati Merati, Anchalee Avihingsanon, Wing-Wai Wong, Man Po Lee, Romanee Chaiwarith, Adeeba Kamarulzaman, Pacharee Kantipong, Fujie Zhang, Jun Yong Choi, Nagalingeswaran Kumarasamy, Rossana Ditangco, Do Duy Cuong, Shinichi Oka, Benedict Lim Heng Sim, Winai Ratanasuwan, Penh Sun Ly, Evy Yunihastuti, Sanjay Pujari, Jeremy L. Ross, Matthew Law, Somnuek Sungkanuparph, on behalf of the TREAT Asia HIV Observational Databases (TAHOD)
Format: Article
Language:English
Published: BMC 2017-05-01
Series:AIDS Research and Therapy
Subjects:
Abacavir
HIV RNA
Model
Prediction
Rilpivirine
Online Access:http://link.springer.com/article/10.1186/s12981-017-0151-1

Internet

http://link.springer.com/article/10.1186/s12981-017-0151-1

Similar Items